BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes

BACKGROUND: B and T lymphocyte attenuator (BTLA) is a novel immune checkpoint with an unclear role in non–small-cell lung cancer (NSCLC). In contrast, the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint is a potentially curative immunotherapy target in NSCLC. Our study investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiangmin, Xu, Zhaoguo, Cui, Guoyuan, Yu, Li, Zhang, Xiaoye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957103/
https://www.ncbi.nlm.nih.gov/pubmed/32021268
http://dx.doi.org/10.2147/OTT.S232234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957103/
https://www.ncbi.nlm.nih.gov/pubmed/32021268
http://dx.doi.org/10.2147/OTT.S232234

Ejemplares similares